choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Tasigna

Tasigna Newsletter
  • FDA Approves Scemblix for Some With Newly Diagnosed Chronic Myeloid Leukemia 29 Oct 2024 19:05 GMT

    … Food and Drug Administration (FDA) for the treatment of adults … kinase inhibitor, which included Tasigna (nilotinib), Gleevec (imatinib), … from the ASC4FIRST trial were presented at … treatment paradigm in [chronic myeloid leukemia].” For more news on cancer …

  • Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups 10 Dec 2024 22:55 GMT

    … subgroups. CancerNetwork® spoke with Andorsky, medical oncologist, hematologist … generation TKIs: nilotinib [Tasigna], dasatinib [Sprycel], or … ], and also fewer treatment discontinuations, interruptions, or … diagnosed chronic myeloid leukemia in chronic phase …

  • Oncology Drugs, Diagnostics Approved by the FDA in November 2024 02 Dec 2024 16:48 GMT

    … Food and Drug Administration (FDA) for diseases including leukemia, biliary tract cancer and other … medications for chronic myeloid leukemia. This can significantly improve patient adherence to treatment …

  • Azurity Announces FDA Approval of Danziten Tablets 26 Nov 2024 14:24 GMT

    … MA—Azurity Pharmaceuticals, Inc., announced that the FDA has approved … chromosome positive chronic myeloid leukemia (Ph+ CML) in … CEO of Azurity Pharmaceuticals, Inc. “Unlike Tasigna, the boxed … including patient adherence to treatment. Danziten has the …

  • FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML 15 Nov 2024 21:51 GMT

    … chromosome positive chronic myeloid leukemia (Ph+ CML) in … to take their medication in a fasted state … for treatment discontinuation. REFERENCES Azurity Pharmaceuticals, Inc. announces FDA approval … tinyurl.com/m3ntv5s5 Tasigna. Novartis. Updated June 2010 …

  • FDA Approves Danziten for Leukemia Subset That Does Not Require Fasting 15 Nov 2024 19:18 GMT

    … of Tasigna,” Richard Blackburn, CEO of Azurity Pharmaceuticals, said … medication in a fasted state, liberating (chronic myeloid leukemia) … drug is meant to block certain proteins that may prevent cancer … chronic myeloid leukemia who respond to treatment has been …

  • Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase 14 Nov 2024 22:45 GMT

    … leukemia (CML), according to a press release from developers Azurity Pharmaceuticals … original formulation of nilotinib (Tasigna) has variable bioavailability, … present inappropriately when treatment with the original … to take their medication in a fasted …

  • FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML 15 Nov 2024 01:15 GMT

    … Ph)–positive chronic myeloid leukemia (CML) in … Tasigna) was initially approved by the FDA in 2007 for the treatment … trials are listed in the clinical trial … drugsatfda_docs/label/2010/022068s004s005lbl.pdf Danziten. Azurity Pharmaceuticals …

  • FDA Grants New Nilotinib Formulation Approval to Treat Adults With Chronic Myeloid Leukemia 15 Nov 2024 20:50 GMT

    … taking the drug. In clinical trials, re-formulated … of Tasigna,” Richard Blackburn, CEO of Azurity Pharmaceuticals, … from the Anderson Cancer Center in Houston, … Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia …

  • FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment 15 Nov 2024 18:09 GMT

    The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), … with current therapies. While Tasigna, the existing nilotinib treatment, has proven efficacy … for patients to take their medication in a fasted state, …

Satisfied with the content?

Continue to create your account.